2-溴-5-氯吡嗪 | 912773-21-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-溴-5-氯吡嗪
• 英文名称: 2-bromo-5-chloropyrazine
• 英文别名: 2-chloro-5-bromopyrazine
• CAS: 912773-21-8
• 化学式: C₄H₂BrClN₂
• 分子量: 193.43
• InChiKey: UXCPLGLOAZWCKO-UHFFFAOYSA-N

物化性质

• 沸点：
  208℃
• 密度：
  1.859
• 闪点：
  80℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-chloropyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-chloropyrazine
CAS number: 912773-21-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H2BrClN2
Molecular weight: 193.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-5-氯吡嗪 、 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]pyridine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以70%的产率得到2-chloro-5-[5-fluoro-6-[(1R)-2,2,2-trifluoro-1-methyl-ethoxy]-3-pyridyl]pyrazine
  参考文献：
  名称：

  ION CHANNEL MODULATORS

  摘要：

  提供了Formula I的化合物及其药用盐，以及与之相关的药物组合物，用于治疗与钠通道活性有关的疾病。本文还提供了治疗与钠离子通道异常功能有关的疾病或症状的方法，包括神经系统疾病（例如，Dravet综合征，癫痫）、疼痛和神经肌肉疾病。

  公开号：

  US20200377507A1
• 作为产物：
  描述：

  5-氯吡嗪-2-羧酸 在 tetrakis(acetonitrile)copper(I)tetrafluoroborate 、 1,3-二溴-5,5-二甲基海因 、 1-fluoro-2,4,6-trimethylpyridin-1-ium tetrafluoroborate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以51%的产率得到2-溴-5-氯吡嗪
  参考文献：
  名称：

  （杂）芳基羧酸脱羧卤化的统一方法

  摘要：

  芳基卤化物是合成化学中的基本基序，在金属介导的交叉偶联反应中起着关键作用，并在药物发现中充当重要的支架。尽管芳基羧酸的热脱羧官能化已得到广泛探索，但现有的卤代脱羧方法的范围仍然有限，并且目前不存在提供从芳基羧酸前体获得任何类型的芳基卤化物的统一策略。在此，我们报告了一种通过配体到金属电荷转移对（杂）芳基羧酸进行直接脱羧卤化的通用催化方法。该策略适用于极其广泛的底物范围。我们利用芳基自由基中间体实现不同的功能化途径：(1) 原子转移以获取溴代或碘代（杂）芳烃或（2）自由基被铜捕获并随后还原消除以生成氯代或氟代（杂）芳烃。所提出的配体到金属的电荷转移机制得到了一系列光谱研究的支持。

  DOI：

  10.1021/jacs.2c02392

文献信息

• [EN] AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126731A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为：(I)，其中A、B、R1、X1、X2和W如本文所述。
• [EN] SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS<br/>[FR] COMPOSÉS DE N-(MÉTHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OU DE N-(MÉTHYL-D3)-NICOTINAMIDE SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS D'IL-12, IL-23 ET/OU IFNALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021222153A1

  公开（公告）日：2021-11-04

  There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating inflammatory and autoimmune diseases or disorders.

  以下是公开的化合物的化学式I或其立体异构体或药用可接受的盐，其中所有取代基如本文所定义，这些化合物在通过作用于Tyk-2引起信号转导抑制的调节IL-12、IL-23和/或IFNγ方面是有用的。本发明的化合物可能对治疗炎症性和自身免疫性疾病或紊乱有用。
• [EN] CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4<br/>[FR] HYDROPYRROLES SUBSTITUÉS CONDENSÉS UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
  申请人：UNIV VANDERBILT

  公开号：WO2021216949A1

  公开（公告）日：2021-10-28

  Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

  本文披露了替代的六氢-1H-环戊[c]吡咯化合物，可能作为肌氨酸乙酰胆碱受体M4（mAChR M4）的拮抗剂。本文还披露了制备这些化合物的方法，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗疾病的方法。
• [EN] IL-17A MODULATORS<br/>[FR] MODULATEURS DE IL-17A
  申请人：SANOFI SA

  公开号：WO2021239745A1

  公开（公告）日：2021-12-02

  The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.

  本发明涉及一种具有IL-17A调节剂作用的化合物。这些化合物具有本文中定义的结构式I。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗与IL-17A活性调节相关的疾病或疾病中的应用。
• [EN] BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE<br/>[FR] DÉRIVÉS DE THIAZINE ET D'OXAZINE BICYCLIQUES EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2018112084A1

  公开（公告）日：2018-06-21

  The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer 's disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

  本公开提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般式（I）：（式（I）），其中式（I）中的变量X、Y、R2、R3、R4、R5、R6和n在此处定义。本公开还提供了包括这些化合物的药物组合物，以及这些化合物和组合物用于治疗与Aβ斑块形成和沉积相关的疾病和/或症状的用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍和其他中枢神经系统疾病。